Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00843310 | Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma | terminated | Phase 2 | 8 | NYU Langone HealthOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00148317 | Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma | completed | Phase 2 | 38 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 18, 2017 | clinicaltrials |
| NCT02098109 | Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | completed | Phase 2 | 100 | Washington University School of MedicineOTHER | 1 | Jul 18, 2017 | clinicaltrials |
| NCT03210753 | Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma | unknown | — | 400 | National Taiwan University HospitalOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00006244 | Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma | completed | Phase 2 | 36 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT01460420 | Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation(EMN-alloRIC) | completed | Phase 1 / Phase 2 | 49 | European Myeloma Network B.V.NETWORK | 4 | Jul 6, 2017 | clinicaltrials |
| NCT02658396 | GO-203-2C + Bortezomib For Relapsed Or Refractory MM | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT00222105 | A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life | completed | Phase 2 | 25 | University of Kansas Medical CenterOTHER | 0 | Jul 2, 2017 | clinicaltrials |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | N/A | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT00417040 | Collection of Patient-Reported Symptoms and Performance Status Via the Internet | completed | N/A | 325 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT01653106 | Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients | completed | N/A | 148 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT00182663 | Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant | completed | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01775553 | Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib | completed | Phase 2 | 13 | Ajai ChariOTHER | 1 | Jun 21, 2017 | clinicaltrials |
| NCT01251952 | Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation | terminated | Phase 1 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT00473590 | A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)(AMBER) | completed | Phase 2 | 102 | Genentech, Inc.INDUSTRY | 0 | Jun 14, 2017 | clinicaltrials |
| NCT01548573 | Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | terminated | Phase 2 | 19 | University of IowaOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01965834 | Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma | terminated | Phase 2 | 6 | University of MiamiOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT02619812 | Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT | terminated | Phase 2 | 4 | Mayo ClinicOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00241358 | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 92 | Washington University School of MedicineOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT01158118 | Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors | completed | Phase 2 | 48 | Washington University School of MedicineOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT00724568 | Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma(RVDD) | completed | Phase 1 / Phase 2 | 74 | University of Michigan Rogel Cancer CenterOTHER | 2 | Jun 2, 2017 | clinicaltrials |
| NCT00676806 | A Phase II Study of Umbilical Cord Blood Transplantation | terminated | Phase 2 | 7 | Tufts Medical CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT01018927 | Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects | terminated | — | 44 | University of ArkansasOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01729338 | Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | terminated | Phase 2 | 17 | Duke UniversityOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00603447 | Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma | completed | Phase 1 | 84 | AmgenINDUSTRY | 2 | May 30, 2017 | clinicaltrials |
| NCT01980589 | A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects(CHAMPION 2) | completed | Phase 1 | 22 | AmgenINDUSTRY | 1 | May 30, 2017 | clinicaltrials |
| NCT01582295 | XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease | completed | Phase 1 | 4 | Massachusetts General HospitalOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT00112593 | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | completed | N/A | 5 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01110135 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | completed | Phase 2 | 43 | University of WashingtonOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00934232 | Busulfan in Multiple Myeloma | terminated | Phase 1 | 13 | Guido TricotOTHER | 0 | May 23, 2017 | clinicaltrials |
| NCT01432600 | Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide | completed | Phase 1 / Phase 2 | 80 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01313897 | UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma(NK2010-35) | completed | Phase 2 | 10 | University of ArkansasOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00619684 | Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant | completed | Phase 2 | 18 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00075478 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | completed | Phase 3 | 87 | Fred Hutchinson Cancer CenterOTHER | 3 | May 15, 2017 | clinicaltrials |
| NCT00642395 | Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT) | completed | Phase 2 | 61 | University Hospital, ToulouseOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT01206205 | Frontline Therapy in de Novo Multiple Myeloma Patients Under 65(IFM2008) | completed | Phase 2 | 31 | University Hospital, ToulouseOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT02260414 | Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer(METRO B) | completed | Phase 2 | 19 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | May 11, 2017 | clinicaltrials |
| NCT03147326 | Diagnostic Imaging of Myeloma Bone Lesions(RAMP) | completed | N/A | 14 | Herlev HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01610999 | Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation | terminated | Phase 1 | 7 | Tufts Medical CenterOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01056276 | Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy | completed | Phase 2 | 59 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT00150462 | Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | completed | Phase 1 | 48 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT00530816 | Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma | completed | Phase 2 | 164 | AmgenINDUSTRY | 2 | May 2, 2017 | clinicaltrials |
| NCT01302392 | A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma(FOCUS) | completed | Phase 3 | 315 | AmgenINDUSTRY | 19 | May 2, 2017 | clinicaltrials |
| NCT01410500 | Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease | approved for marketing | — | — | AmgenINDUSTRY | 0 | May 2, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jul 19, 2017source: clinicaltrials